Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-003076-39
    Sponsor's Protocol Code Number:ARGX-113-1802
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-003076-39
    A.3Full title of the trial
    A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Sperimentazione di fase 2 per valutare l'efficacia, la sicurezza, e la tollerabilità di efgartigimod PH20 SC in pazienti adulti affetti da polineuropatia demielinizzante infiammatoria cronica (CIDP)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyelinating polyneuropathy (an autoimmune disorder that affects the peripheral nerves)
    Studio per valutare la sicurezza e l'efficacia di una formulazione sottocutanea di efgartigimod in adulti affetti da polineuropatia demielinizzante infiammatoria cronica (un disturbo autoimmune che colpisce i nervi periferici)
    A.3.2Name or abbreviated title of the trial where available
    ADHERE
    ADHERE
    A.4.1Sponsor's protocol code numberARGX-113-1802
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorARGENX BV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportargenx BV
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationargenx BVBA
    B.5.2Functional name of contact pointRegulatory
    B.5.3 Address:
    B.5.3.1Street AddressIndustriepark Zwijnaarde 7
    B.5.3.2Town/ cityZwijnaarde
    B.5.3.3Post code9052
    B.5.3.4CountryBelgium
    B.5.4Telephone number003293103400
    B.5.6E-mailregulatory@argenx.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEfgartigimod PH20 SC
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEfgartigimod alfa
    D.3.9.1CAS number 1821402-21-4
    D.3.9.2Current sponsor codeARGX-113
    D.3.9.3Other descriptive nameARGX-113
    D.3.9.4EV Substance CodeSUB180001
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number165
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Inflammatory Demyelinating Polyneuropathy
    Polineuropatia demielinizzante infiammatoria cronica
    E.1.1.1Medical condition in easily understood language
    Inflammation of peripheral nervous system
    Infiammazione del sistema nervoso periferico
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10077384
    E.1.2Term Chronic inflammatory demyelinating polyneuropathy
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Stage A:
    To assess the activity of efgartigimod PH20 SC (efgartigimod co-formulated with recombinant human hyaluronidase PH20 [rHuPH20]) based on the percentage of patients classified as treatment responders.

    Stage B:
    To determine the efficacy of efgartigimod PH20 SC compared to placebo based on the time needed for the occurrence of the first evidence of clinical deterioration.
    Parte A:
    Valutare l'attività di efgartigimod PH20 SC (efgartigimod co-formulato con ialuronidasi umana ricombinante PH20 [rHuPH20]) in base alla percentuale di pazienti classificati come rispondenti al trattamento.

    Parte B:
    Determinare l'efficacia di efgartigimod PH20 SC rispetto al placebo in base al tempo necessario per il verificarsi della prima evidenza di peggioramento clinico.
    E.2.2Secondary objectives of the trial
    Stage A:
    - To assess the time to clinical improvement.
    -To determine the treatment effect of efgartigimod PH20 SC based on clinical functional assessments of motor function and muscle strength.
    -To assess the short-term safety and tolerability of efgartigimod PH20 SC.
    -To assess the pharmacokinetics (PK) of efgartigimod PH20 SC.
    -To assess the pharmacodynamic (PD) effect of efgartigimod PH20 SC.
    -To assess the immunogenicity of efgartigimod and rHuPH20.

    Stage B:
    -To determine the efficacy of efgartigimod PH20 SC compared to placebo based on clinical functional assessments of disease disability and motor function and muscle strength.
    -To assess the safety and tolerability of efgartigimod PH20 SC.
    -To assess the PK of efgartigimod PH20 SC.
    -To assess the PD effect of efgartigimod PH20 SC.
    -To assess the immunogenicity of efgartigimod and rHuPH20.
    Parte A:
    -Valutare il tempo al miglioramento clinico.
    -Determinare l'effetto del trattamento con efgartigimod PH20 SC sulla base di valutazioni cliniche funzionali della funzione motoria e della forza muscolare.
    -Valutare la sicurezza e la tollerabilità a breve termine di efgartigimod PH20 SC.
    -Valutare la farmacocinetica (Pharmacokinetics, [PK]) di efgartigimod PH20 SC.
    -Valutare l’effetto farmacodinamico (Pharmacodynamic, [PD]) di efgartigimod PH20 SC.
    -Valutare l’immunogenicità di efgartigimod e rHuPH20.

    Parte B:
    -Determinare l'efficacia di efgartigimod PH20 SC rispetto al placebo sulla base di valutazioni cliniche funzionali dell’invalidità legata alla malattia, della funzione motoria e della forza muscolare.
    -Valutare la sicurezza e la tollerabilità di efgartigimod PH20 SC.
    -Valutare la PK di efgartigimod PH20 SC.
    -Valutare l’effetto PD di efgartigimod PH20 SC.
    -Valutare l’immunogenicità di efgartigimod e rHuPH20.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients are eligible to be included in the trial only if all of the following criteria apply:
    1. Ability to understand the requirements of the trial, provide written informed consent (include consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits)
    2. Male or female patient aged 18 years or older, at the time of signing the informed consent.
    3. Diagnosed with probable or definite CIDP according to criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010), progressing or relapsing forms.
    4. CIDP Disease Activity Status (CDAS) score =2 at screening
    5. INCAT score > = 2, with a score of 2 exclusively from leg disability at the first run-in visit (RI-VI; for patients entering run-in) or stage A baseline (A-VI; for treatment-naïve patients with documented evidence for worsening on the total adjusted INCAT disability score within 3 months prior to screening)
    6. Fulfilling any of the following treatment conditions:
    -Currently treated with pulsed corticosteroids, oral corticosteroids equivalent to prednisolone/prednisone =10mg/day, and/or IVIg or SCIg, if this treatment has been started within the last 5 years before screening, and the patient is willing to discontinue this treatment at the first run-in visit (RI-VI); or
    -Without previous treatment (treatment-naive); or
    -Treatment with corticosteroids and/or IVIg or SCIg discontinued at least 6 months prior to screening
    Note: Patients not treated with monthly or daily corticosteroids, IVIg or SCIg for at least 6 months prior to screening are considered as equal to treatment-naïve patients.
    7. Women of childbearing potential who have a negative pregnancy test at screening and a negative urine pregnancy test up to Stage A baseline (D1A).
    8. Women of childbearing potential must use a highly effective method of contraception (failure rate of less than 1% per year) from screening to 90 days after the last administration of IMP
    9. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom and his partner must use a highly effective method of contraception (failure rate of less than 1% per year) from screening to 90 days after the last administration of IMP . Male patients practicing true sexual abstinence (when this is in line with the preferred and usual life style of the participant) can be included. Sterilized male patients who have had vasectomy with documented aspermia post-procedure can be included.
    In addition, male patients are not allowed to donate sperm from screening to 90 days after the last administration of IMP
    I pazienti sono idonei all’inclusione nella sperimentazione solo se sono soddisfatti tutti i seguenti criteri:
    1. Capacità di comprendere i requisiti della sperimentazione, di fornire il consenso informato scritto (che include il consenso all'uso e alla divulgazione di informazioni sanitarie correlate alla ricerca), volontà e capacità di attenersi alle procedure relative al protocollo della sperimentazione (incluse le visite della sperimentazione richieste).
    2. Paziente di sesso maschile o femminile, di età pari o superiore a 18 anni al momento della firma del consenso informato.
    3. Diagnosi di polineuropatia demielinizzante infiammatoria cronica (Chronic Inflammatory Demyelinating Polyneuropathy, [CIDP]) certa o probabile in base ai criteri della European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010), nelle forme progressiva o recidivante.
    4. Punteggio dello stato di attività della malattia CIDP (CIDP Disease Activity Status, [CDAS]) = 2 allo screening.
    5. Punteggio INCAT > = 2, con un punteggio di 2 esclusivamente dovuto alla disabilità alla gamba, alla prima visita di run-in (RI-VI; per i pazienti che entrano nel run-in) o al basale della Parte A (A-VI; per pazienti naïve al trattamento con evidenza documentata di peggioramento del punteggio di invalidità INCAT aggiustato totale nei 3 mesi precedenti lo screening)
    6. Soddisfacimento di una qualsiasi delle seguenti condizioni di trattamento:
    -Attuale trattamento con corticosteroidi pulsati, corticosteroidi orali equivalenti a prednisone/prednisolone = 10 mg/die e/o immunoglobuline per via endovensosa (Intravenous Immunoglobulin, [IVIg]) o immunoglobuline per via sottocutanea (Subcutaneous Immunoglobulin, [SCIg]), se questo trattamento è stato iniziato entro gli ultimi 5 anni precedenti lo screening e il paziente è disposto a interrompere questo trattamento alla prima visita di run-in (Run-In Visit, [RI-VI]); oppure
    -Senza precedente terapia (naïve al trattamento); oppure
    -Trattamento con corticosteroidi e/o IVIg o SCIg interrotto almeno 6 mesi prima dello screening.
    Nota: i pazienti non trattati mensilmente o giornalmente con corticosteroidi, IVIg o SCIg per almeno 6 mesi prima dello screening sono considerati equivalenti ai pazienti naïve al trattamento.
    7. Le donne in età fertile devono risultare negative al test di gravidanza allo screening e devono presentare un test di gravidanza sulle urine negativo fino al basale della Parte A (G1A).
    8. Le donne in età fertile devono utilizzare un metodo altamente efficace di contraccezione (tasso di fallimento inferiore all'1% all’anno) dallo screening a 90 giorni dopo l'ultima somministrazione dell’IMP.
    9. I pazienti di sesso maschile non sterilizzati, che sono sessualmente attivi con una partner di sesso femminile in età fertile, devono utilizzare un preservativo e la partner deve usare un metodo contraccettivo altamente efficace (tasso di fallimento inferiore all'1% all'anno) dallo screening fino a 90 giorni dopo l'ultima somministrazione dell’IMP. I pazienti di sesso maschile che praticano astinenza sessuale completa (quando in linea con lo stile di vita preferito e abituale del partecipante) possono essere inclusi. I pazienti di sesso maschile sterilizzati, che hanno subito una vasectomia con aspermia post-procedurale documentata, possono essere inclusi.
    Inoltre, ai pazienti di sesso maschile non è consentito donare sperma a partire dallo screening fino a 90 giorni dopo l'ultima somministrazione dell’IMP.
    E.4Principal exclusion criteria
    Patients are excluded from the trial if any of the following criteria apply:
    1. Pure sensory atypical CIDP (EFNS/PNS definition(11)).
    2. Polyneuropathy of other causes, including the following:
    -Multifocal motor neuropathy;
    - Monoclonal gammopathy of uncertain significance with anti-myelinassociated
    glycoprotein immunoglobulin M (IgM) antibodies;
    -Hereditary demyelinating neuropathy;
    -Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes;
    -Lumbosacral radiculoplexus neuropathy;
    -Polyneuropathy most likely due to diabetes mellitus;
    -Polyneuropathy most likely due to systemic illnesses;
    -Drug- or toxin-induced polyneuropathy.
    3. Any other disease that could better explain the patient's signs and symptoms.
    4. Any history of myelopathy or evidence of central demyelination.
    5. Current or past history (within 12 months of screening) of alcohol, drug or medication abuse.
    6. Severe psychiatric disorder (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation that in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol.
    7. Patients with clinically significant active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including patients who test positive for an active viral infection at screening with:
    - Active Hepatitis B Virus (HBV): serologic panel test results indicative of an active (acute or chronic) infection;
    - Active Hepatitis C Virus (HCV): serology positive for HCV-Ab;
    - Human Immunodeficiency Virus (HIV) positive serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining condition or with a cluster of differentiation 4 (CD4) count =200 cells/mm3.
    8. Total IgG level <6 g/L at screening.
    9. Treatment with the following:
    -Within 3 months (or 5 half-lives of the drug, whichever is longer) before screening: plasma exchange or immunoadsorption, any concomitant Fc containing therapeutic agents or other biological, or any other investigational product;
    -Within 6 months before screening: rituximab, alemtuzumab, any other monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor–alpha inhibitors, fingolimod, methotrexate, azathioprine, mycophenolate, any other immunomodulating or immunosuppressive medications, and oral daily corticosteroids >10 mg/day.
    Note: Patients using IVIg, SCIg, pulsed corticosteroids, and oral daily corticosteroids =10 mg/day can be included.
    10. Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after last IMP administration.
    11. Patients with any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of CIDP.
    12. Patients who received a live-attenuated vaccine fewer than 28 days before screening. Receiving an inactivated, sub-unit, polysaccharide, or conjugate vaccine any time before screening is not exclusionary.
    For additional infomation about exclusion criteria please refer to Protocol.
    I pazienti saranno esclusi dalla sperimentazione se rientreranno in uno qualsiasi dei seguenti criteri:
    1. CIDP atipica sensoriale pura (definizione EFNS/PNS (11)).
    2. Polineuropatia dovuta ad altre cause, tra cui le seguenti:
    -Neuropatia motoria multifocale;
    -Gammopatia monoclonale di incerta significatività con anticorpi immunoglobuline M (IgM) anti-glicoproteina associata alla mielina;
    -Neuropatia demielinizzante ereditaria;
    -Sindromi con polineuropatia, organomegalia, endocrinopatia, proteine monoclonali e alterazioni cutanee;
    -Radicoloplessopatia lombosacrale;
    -Polineuropatia molto probabilmente dovuta a diabete mellito;
    -Polineuropatia molto probabilmente dovuta a malattie sistemiche;
    -Polineuropatia indotta da farmaci o tossine.
    3. Qualsiasi altra malattia che potrebbe spiegare meglio i segni e i sintomi del paziente.
    4. Qualsiasi anamnesi di mielopatia o evidenza di demielinizzazione centrale.
    5. Anamnesi attuale o pregressa (entro 12 mesi dallo screening) di abuso di alcol, farmaci o sostanze stupefacenti.
    6. Gravi disturbi psichiatrici (quali depressione grave, psicosi, disturbo bipolare), anamnesi di tentativo di suicidio o attuale ideazione suicidaria che, a giudizio dello sperimentatore, potrebbero creare un rischio eccessivo per il paziente o potrebbero compromettere l'aderenza al protocollo della sperimentazione.
    7. I pazienti con infezione batterica, virale o fungina, non controllata attiva o cronica clinicamente significativa allo screening, compresi i pazienti che presentano un test positivo a un’infezione virale attiva allo screening con:
    - Virus dell’epatite B (Hepatitis B Virus, [HBV]) attivo: risultati del test profilo sierologico indicativi di un’infezione attiva (acuta o cronica);
    - Virus dell’epatite C (Hepatitis C Virus, [HCV]) attiva: test sierologico positivo per anticorpi anti-HCV (HCV-Antibody, [HCV-Ab]);
    - Test sierologico positivo per infezione da virus dell'immunodeficienza umana (Human Immunodeficiency Virus, [HIV]) associato a una condizione di definizione della sindrome da immunodeficienza acquisita (Acquired Immune Deficiency Syndrome, [AIDS]) o con una conta di cluster di differenziazione 4 (Cluster of Dfferentiation 4, [CD4]) = 200 cellule/mm3.
    8. Livello di IgG totale < 6 g/l allo screening.
    9. In presenza dei seguenti trattamenti:
    -Entro 3 mesi (o 5 emivite del farmaco, a seconda di quale periodo sia più lungo) prima dello screening: plasmaferesi o immunoadsorbimento, qualsiasi Fc concomitante contenente agenti terapeutici o altro farmaco biologico o qualsiasi altro prodotto sperimentale;
    -Entro 6 mesi prima dello screening: rituximab, alemtuzumab, qualsiasi altro anticorpo monoclonale, ciclofosfamide, interferone, inibitori del fattore di necrosi tumorale alfa, fingolimod, metotrexato, azatioprina, micofenolato, eventuali altri farmaci immunomodulatori o immunosoppressori e corticosteroidi orali giornalieri = 10 mg/die.
    Nota: i pazienti in trattamento con IVIg, SCIg, corticosteroidi pulsati e corticosteroidi orali giornalieri = 10 mg/die possono essere inclusi.
    10. Donne in stato di gravidanza e in allattamento e coloro che desiderano una gravidanza durante la sperimentazione o entro 90 giorni dopo l'ultima somministrazione dell'IMP.
    11. Pazienti con qualsiasi altra malattia autoimmune nota che, a parere dello sperimentatore, interferirebbe con una valutazione accurata dei sintomi clinici della CIDP.
    12. Pazienti che ricevono un vaccino vivo attenuato. Ricevere un vaccino inattivato, a subunità, polisaccaridico o coniugato in qualsiasi momento prima dello screening non esclude dalla partecipazione alla sperimentazione.
    Per informazioni aggiuntive sui criteri di esclusione si prega di far riferimento al Protocollo
    E.5 End points
    E.5.1Primary end point(s)
    Stage A
    Percentage of patients with confirmed evidence of clinical improvement (ECI).

    Stage B
    Stage B: Time to first adjusted INCAT deterioration compared to Stage B baseline
    Parte A:
    Percentuale di pazienti con evidenza confermata di un miglioramento clinico (Evidence of Clinical Improvement, [ECI]).

    Parte B:
    Tempo al primo deterioramento INCAT corretto rispetto al basale della Parte B
    E.5.1.1Timepoint(s) of evaluation of this end point
    Stage A
    Up to 12 weeks (with option 1 additional week for confirmation of ECI) during the open-label stage A

    Stage B
    Every Stage B visit
    Parte A:
    Un massimo di 12 settimane (con l’opzione di 1 ulteriore settimana per la conferma dell’ECI) durante la Parte A in aperto

    Parte B:
    Ogni visita della Parte B
    E.5.2Secondary end point(s)
    Stage A:
    - Time to initial confirmed ECI
    - Change from Stage A baseline (D1A) over time in adjusted INCAT score
    - Change from Stage A baseline (D1A) over time in Medical Research Council (MRC) Sum score
    - Change from Stage A baseline (D1A) over time in 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS) disability scores
    - Change from Stage A baseline (D1A) over time in Timed Up-and-go (TUG) score
    - Change from Stage A baseline (D1A) over time in Mean grip strength
    - Exposure adjusted occurrence of treatment-emergent adverse events and serious adverse events
    - Incidence of clinically significant laboratory abnormalities
    - Pre-dosing efgartigimod serum concentrations over time
    - Changes of serum IgG levels (total and IgG subtypes) over time
    - Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20

    Stage B
    - Time to CIDP disease progression.
    Note: Time to CIDP disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease =4 points compared to Stage B baseline using the centile metric.
    - Percentage of patients with improved functional level compared to Stage B baseline as measured by an increase in the 24-item I-RODS score up to Week 48
    - Change from Stage B baseline over time in adjusted INCAT score
    - Change from Stage B baseline over time in MRC Sum score
    - Change from Stage B baseline over time in 24-item I-RODS disability score
    - Change from Stage B baseline over time in TUG score
    - Change from Stage B baseline over time in mean grip strength
    - Time to 10% decrease in the 24-item I-RODS
    - Exposure adjusted occurrence of treatment-emergent adverse events and serious adverse events
    - Incidence of clinically significant laboratory abnormalities
    - Pre-dosing efgartigimod serum concentrations over time
    - Changes of serum IgG levels (total and IgG subtypes) over time
    - Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20
    Parte A:
    - Tempo alla conferma iniziale dell’ECI
    - Variazioni nel tempo rispetto al basale della Parte A (G1A) in termini di punteggio INCAT aggiustato
    - Variazioni nel tempo rispetto al basale della Parte A (G1A) in termini di punteggio della somma del Medical Research Council (MRC)
    - Variazioni nel tempo rispetto al basale della Parte A (G1A) in termini di punteggi di invalidità dell’Inflammatory Rasch-built Overall Disability Scale (I-RODS) a 24 item
    - Variazioni nel tempo rispetto al basale della Parte A (G1A) in termini di punteggio Timed Up-and-Go (TUG)
    - Variazioni nel tempo rispetto al basale della Parte A (G1A) in termini di forza di presa media
    - Comparsa aggiustata per esposizione di eventi avversi emergenti dal trattamento e di eventi avversi seri
    - Incidenza di anomalie di laboratorio clinicamente significative
    - Concentrazioni sieriche pre-dosaggio di efgartigimod nel tempo
    - Variazioni nel tempo dei livelli sierici di IgG (totale e sottotipi IgG)
    - Percentuale di pazienti con e titoli di anticorpi leganti verso efgartigimod e/o rHuPH20 e presenza di anticorpi neutralizzanti diretti contro efgartigimod e/o rHuPH20

    Parte B:
    - Tempo alla progressione della malattia CIDP.
    Nota: il tempo alla progressione della malattia CIDP è definito dal tempo intercorso dalla prima dose dell’IMP in doppio cieco alla prima diminuzione del punteggio I-RODS = 4 punti rispetto al basale della Parte B utilizzando i percentili.
    - Percentuale di pazienti con miglioramento del livello funzionale rispetto al basale della Parte B, misurato da un aumento del punteggio I-RODS a 24 item fino alla Settimana 48
    - Variazione nel tempo rispetto al basale della Parte B in termini di punteggio INCAT aggiustato
    - Variazione nel tempo rispetto al basale della Parte B in termini di punteggio della somma MRC
    - Variazione nel tempo rispetto al basale della Parte B in termini del punteggio dell’invalidità I-RODS a 24 item
    - Variazione nel tempo rispetto al basale della Parte B in termini di punteggio TUG
    - Variazione nel tempo rispetto al basale della Parte B in termini di forza di presa media
    - Tempo alla riduzione del 10% nella scala I-RODS a 24 item
    - Comparsa aggiustata per esposizione di eventi avversi emergenti dal trattamento ed eventi avversi seri
    - Incidenza di anomalie di laboratorio clinicamente significative
    - Concentrazioni sieriche pre-dosaggio di efgartigimod nel tempo
    - Variazioni nel tempo dei livelli sierici di IgG (totale e sottotipi IgG)
    - Percentuale di pazienti con e titoli di anticorpi leganti verso efgartigimod e/o rHuPH20 e presenza di anticorpi neutralizzanti diretti contro efgartigimod e/o rHuPH20.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Stage A
    Up to 12 weeks (with option 1 additional week for confirmation of ECI) during the open-label stage A
    Stage B
    Up to 48 weeks during the randomized placebo-controlled stage B
    Parte A:
    Un massimo di 12 settimane (con l’opzione di 1 ulteriore settimana per la conferma dell’ECI) durante la Parte A in aperto

    Parte B:
    Un massimo di 48 settimane durante la Parte B randomizzata controllata verso placebo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    Immunogenicità
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Parte A in aperto e Parte B con ritiro randomizzato, in doppio cieco, controllata con placebo
    Open-label Stage A and randomized-withdrawal double-blinded, placebo-controlled Stage B
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA61
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Georgia
    Israel
    Japan
    Russian Federation
    Serbia
    Ukraine
    United States
    Belgium
    Bulgaria
    Denmark
    France
    Germany
    Hungary
    Italy
    Latvia
    Netherlands
    Poland
    Romania
    Spain
    United Kingdom
    Czechia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of trial is defined as the last patient last visit in the ARGX-113- 1802 trial, ie, any of the following:
    1) the last visit before roll-over to the Open-Label Extension (OLE) trial,
    2) the follow-up visit 28 days after the Week-48 visit for patients not participating in the OLE trial or,
    3) the follow-up visit 28 days after early discontinuation, if applicable.
    La fine della sperimentazione è definita come “ultima visita dell'ultimo paziente nella sperimentazione ARGX-113-1802 ovvero, qualsiasi dei seguenti:
    1) L'ultima visita, prima del roll-over alla sperimentazione di estensione in aperto (Open-Label Extension, [OLE]),
    2) Visita di follow-up 28 giorni dopo la visita della Settimana 48 per i pazienti che non partecipano alla sperimentazione OLE o,
    3) La visita di follow-up 28 giorni dopo l'interruzione anticipata, se pertinente.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 240
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 160
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 193
    F.4.2.2In the whole clinical trial 400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who have clinical deterioration or who complete the Week-48 visit will have the possibility to enter the 4-week safety follow-up period and complete the ARGX-113-1802 trial or have the possibility to enroll for the OLE trial. Patients not eligible for OLE, or not willing to participate in the OLE trial, or have withdrawn/discontinued early, the most appropriate treatment will be provided in accordance with the trial site's standard of care and generally accepted medical practice .
    Pz peggioramento clinico o che completano la visita della W 48 avranno la possibilità di entrare nel FUP di sicurezza di 4 W e di completare la sperimentazione ARGX-113-1802 o avranno la possibilità di arruolarsi per la sperimentazione OLE. Ai pz non eleggibili o non disposti a partecipare alla sper OLE o che si sono ritirati/hanno interrotto in anticipo sarà fornito il trattamento più appropriato in conformità con lo SOC del centro di sperim e con la pratica medica generalmente accettata.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-05-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-04-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-04-26
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 05:40:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA